Published in Pain and Central Nervous System Week, November 7th, 2005
"Combined anticancer therapy using platinum compounds and antitubulins has increased the risk of neurotoxicity. However, the combination of low-dose CDDP with toxic doses of paclitaxel significantly reduces cellular death in a human neuroblastoma SH-SY5Y cell line," investigators in Italy reported.
"To analyze the mechanisms of this protection, we evaluated various signaling molecules possibly involved in apoptosis and some relevant cell cycle regulatory proteins. CDDP does not interfere with the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pain and Central Nervous System Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.